These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 27075693

  • 1. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [Abstract] [Full Text] [Related]

  • 2. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
    Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH.
    World J Gastroenterol; 2015 May 14; 21(18):5668-76. PubMed ID: 25987794
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.
    J Gastroenterol Hepatol; 2011 Mar 14; 26(3):461-8. PubMed ID: 21332543
    [Abstract] [Full Text] [Related]

  • 4. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 May 14; 21(5):335-9. PubMed ID: 24025132
    [Abstract] [Full Text] [Related]

  • 5. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 May 14; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 6. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL.
    Gastroenterology; 2009 Dec 14; 137(6):2002-9. PubMed ID: 19737568
    [Abstract] [Full Text] [Related]

  • 7. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H, Yang RF, Wei L.
    J Gastroenterol Hepatol; 2010 Sep 14; 25(9):1498-506. PubMed ID: 20796146
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct 14; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 10. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Oct 14; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 14; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 14. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct 14; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.
    J Gastrointestin Liver Dis; 2009 Dec 14; 18(4):425-31. PubMed ID: 20076814
    [Abstract] [Full Text] [Related]

  • 16. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.
    Antivir Ther; 2011 Dec 14; 16(5):629-37. PubMed ID: 21817184
    [Abstract] [Full Text] [Related]

  • 17. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.
    J Gastroenterol Hepatol; 2011 Oct 14; 26(10):1527-35. PubMed ID: 21557773
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W.
    J Gastroenterol Hepatol; 2012 Sep 14; 27(9):1447-53. PubMed ID: 22168789
    [Abstract] [Full Text] [Related]

  • 19. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML, Liao J, Wei B, Zhang DM, He M, Tao MC, Chen EQ, Tang H.
    Infect Dis (Lond); 2018 Jul 14; 50(7):522-530. PubMed ID: 29463147
    [Abstract] [Full Text] [Related]

  • 20. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct 14; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.